Introduction: Meningococcal meningitis is a major public health issue in Burkina Faso due to its high morbidity and mortality. This work aims at studying meningococcal meningites thirteen years (13 years) after the nationwide introduction of” MenAfrivac” serogroup A meningococcal vaccine.
Methodology: This was a retrospective cross-sectional study of all epidemiological surveillance data on meningococcal meningitis following the introduction of conjugate A vaccine from 2010 to 2022. It involved all suspected cases of meningitis in Burkina Faso's13 health regions, whose cerebrospinal fluid (CSF) samples were analyzed in the laboratory using the Polymerization Chain Reaction(PCR) technique.
Results: A total number of 27370 suspected cases of meningitis were recorded. Of these, 3125 were PCR-confirmed, including 1155 meningococcal cases, i.e. a frequency of
6.96%, and 76 fatal cases, of which 56 (73.68%) were due to serogroup W. Patients aged [4 - 15] were the most represented (74.12%). Nm serogroups accounted for 0.41% of NmA, 75.17% of NmW and 20.78% of NmX.
Conclusion: This work has highlighted the nearly total disappearance of NmA following the introduction of the A(MenAfrivac) conjugate vaccine, and the emergence and re-emergence of other serogroups. It is therefore imperative to strengthen surveillance, develop and make available a conjugate vaccine that takes into account these serogrou

Meningococcal Meningitis; Serogroups A; W and X; MenAfriVac